NPM1 and acute myeloid leukemia: Improved risk stratification and patient selection for intensive chemotherapy versus allogeneic hematopoietic stem cell transplantation, optimized timing and dosing of venetoclax-based regimens, and the integration of emerging targeted therapies directed at NPM1 or cooperating mutations may collectively enhance outcomes in elderly NPM1-mutated AML patients.